

## Novel Approaches to Treating NASH

### Key Opinion Leader Breakfast

Hosted by Inventiva (private)

The meeting will feature a keynote presentation by **Sven Francque, MD**, (University of Antwerp), who will provide an overview of the nonalcoholic steatohepatitis (NASH) market and discuss current and novel approaches to treatment.

Members of the Inventiva management team will provide an overview of the Company's ongoing development work with **IVA337**, an anti-fibrotic treatment with a unique mechanism of action going through the activation of all three alpha, gamma and delta PPARs (peroxisome proliferator-activated receptors). Inventiva is currently investigating IVA337 in Phase IIb trials for the treatment of NASH as well as systemic sclerosis.

Friday, December 16, 2016  
8:00-9:30 am ET

Lotte NY Palace Hotel  
455 Madison Ave

#### RSVP Information

The event is intended for investors, analysts, investment bankers, and business development professionals only.

Please RSVP in advance if you plan to attend, as space is limited.

To reserve a spot, please reply to this email or contact LifeSci Advisors, LLC at [mac@lifesciadvisors.com](mailto:mac@lifesciadvisors.com).

#### Webcast Information

For those who are unable to attend in person, a live webcast and replay will be accessible here.

[Enter Webcast](#)

#### Q&A Questions

If you would like to ask a question during the live Q&A, please submit your request via email.

[Email Q&A](#)

#### KOL Biography

##### **Sven Francque, MD**

Prof. Dr. Sven Francque is currently Chairman of the Department of Gastroenterology and Hepatology of the University Hospital Antwerp and a Professor of Medicine at the Faculty of Medicine and Health Sciences of the University of Antwerp in Belgium.

He has a long-standing interest and expertise in non-alcoholic fatty liver disease and conducted basic research focusing on the vascular changes in steatosis and their contribution to disease progression. His research unit continues to study pathophysiological mechanisms of NASH. He also conducts clinical research, and his unit is a partner in several research consortia supported by the European Commission. He and his unit participate in most of the clinical trials in the field, and he is a scientific committee member involved in the design of several phase 2 and one of the current phase 3 trials in NAFLD. He is a senior clinical researcher for the Research Fund of the Flemish government.

Prof. Dr. Francque obtained his MD at the University of Antwerp, Belgium, in 1994 and was subsequently trained in internal medicine and in gastroenterology and hepatology at the Antwerp University Hospital, Belgium and at the Department of Hepatology of the Beaujon hospital, Clichy, France.